Extended Anti-Coagulation in VTE Patients and Anticoagulation in Cancer-Associated Thrombosis

Discussion on the use of extended anti-coagulation in VTE patients, the comparison between lower dose DO-X and full-dose DO-X plus aspirin for secondary prevention, and the preference for RIVA-10 over aspirin. Additionally, the chapter covers the historical use of Loma-like red heparin in cancer patients, the shift towards DO-X, and the effectiveness of various RCT trials like Hawkes, Selectee, and Caravaggio in preventing VTE in cancer patients.